Valbazen 100 mg/ml Total Spectrum Wormer oral suspension and associated names, including its generic/hybrid products

Current status:
European Commission final decision

Overview

On 5 November 2020, the European Medicines Agency (the Agency) completed a review of the withdrawal periods (milk, meat and offal) for cattle for Valbazen 100 mg/ml Total Spectrum Wormer oral suspension and associated names, including its generic/hybrid products. The withdrawal period is the minimum time that has to elapse before an animal treated with a medicine can be slaughtered so that its meat or other animal derived products may be used for human consumption.

The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of these medicines continue to outweigh the risks, but that the withdrawal periods for cattle should be changed to provide assurance for consumer safety.

Key facts

Approved name
Valbazen 100 mg/ml Total Spectrum Wormer oral suspension and associated names, including its generic/hybrid products
International non-proprietary name (INN) or common name
albendazole
Reference number
EMEA-V-A-140
Type
Article 35

Community interest referral: initiated in cases involving the interests of the Community or concerns relating to the protection of human or animal health or the environment.

Status
European Commission final decision
Opinion date
05/11/2020
EC decision date
18/01/2021

All documents

Document description

  • Opinion - contains the CVMP opinion of the referred medicine(s)
  • List of the medicines affected by the referral (Annex I)
  • Scientific conclusions of the Committee (Annex II)

The following two documents may not always be available:

How useful was this page?

Add your rating